{"success":true,"data":{"pressRelease":{"id":"139044","rtpr_id":"nGNX90RCBp-20260909","ticker":"NTHI","exchange":"NASDAQ","all_tickers":["NTHI"],"title":"NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors","author":"Globe Newswire","published_at":"2026-09-09T12:00:01.350Z","article_body":"CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies\nHoldings, Inc. (Nasdaq: NTHI) (\"NeOnc\" or the \"Company\"), a multi-Phase 2\nclinical-stage biopharmaceutical company developing novel therapies for\ncentral nervous system (CNS) cancers, today announced that it has entered into\ndefinitive securities purchase agreements with new and existing healthcare\nfocused institutional investors for the purchase and sale of 3,571,430 shares\nof the Company’s common stock (or pre-funded warrants to purchase shares of\ncommon stock in lieu thereof) and accompanying warrants to purchase up to\n3,571,430 shares of the Company’s common stock at a combined purchase price\nof $4.20 per share (or $4.1999 per pre-funded warrant) and accompanying\nwarrant in a registered direct offering priced at-the-market under Nasdaq\nrules. Each pre-funded warrant will be exercisable upon issuance at an\nexercise price of $0.0001 per share and will expire when exercised in full.\nEach warrant will be immediately exercisable at an exercise price of $4.20 per\nshare and will expire five years from the date of issuance.\n\nThe gross proceeds to the Company from the registered direct offering are\nestimated to be approximately $15 million before deducting the placement\nagent’s fees and other estimated offering expenses. The offering is expected\nto close on or about September 10, 2026, subject to the satisfaction of\ncustomary closing conditions.\n\nRoth Capital Partners and A.G.P./Alliance Global Partners are acting as\nco-placement agents.\n\nThe registered direct offering of the securities is being made pursuant to a\nshelf registration statement on Form S-3 (File No. 333-294845) previously\nfiled by the Company with the U.S. Securities and Exchange Commission (\"SEC\")\nand became effective on April 9, 2026. The offering is being made only by\nmeans of a prospectus forming part of the effective registration statement\nrelating to the offering. A final prospectus supplement and accompanying\nprospectus describing the terms of the offering will be filed with the SEC and\nwill be available on the SEC’s website located at https://www.sec.gov.\nElectronic copies of the final prospectus supplement and the accompanying\nprospectus may be obtained, when available, by contacting Roth Capital\nPartners, LLC at 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660,\nAttn: Prospectus Department, telephone: 800-678-9147 or by email at\nrothecm@roth.com, or A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th\nFloor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at\nprospectus@allianceg.com.\n\nThis press release does not constitute an offer to sell or the solicitation of\nan offer to buy, nor will there be any sales of such securities in any\njurisdiction in which such offer, solicitation or sale would be unlawful prior\nto registration or qualification under the securities laws of such\njurisdiction. Copies of the prospectus supplement relating to the registered\ndirect offering, together with the accompanying base prospectus will be filed\nby the Company and, upon filing, can be obtained at the SEC’s website at\nwww.sec.gov.\n\nAbout NeOnc Technologies Holdings, Inc.\n\nNeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company\nfocused on the development and commercialization of central nervous system\ntherapeutics that are designed to address the persistent challenges in\novercoming the blood-brain barrier. The company’s NEO™ drug development\nplatform has produced a portfolio of novel drug candidates and delivery\nmethods with patent protections extending to 2038. These proprietary\nchemotherapy agents have demonstrated positive effects in laboratory tests on\nvarious types of cancers and in clinical trials treating malignant gliomas.\nNeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical\ntrials and are advancing under FDA Fast-Track and Investigational New Drug\n(IND) status. The company has exclusively licensed an extensive worldwide\npatent portfolio from the University of Southern California consisting of\nissued patents and pending applications related to NEO100, NEO212, and other\nproducts from the NeOnc patent family for multiple uses, including oncological\nand neurological conditions.\n\nFor more about NeOnc and its pioneering technology, visit https://neonc.com.\n\nForward-Looking Statements\n\nNeOnc cautions you that all statements, other than statements of historical\nfacts, contained in this press release, are forward-looking statements.\nForward-looking statements, in some cases, can be identified by terms such as\n\"believe,\" \"may,\" \"will,\" \"estimate,\" \"continue,\" \"anticipate,\" \"design,\"\n\"intend,\" \"expect,\" \"could,\" \"plan,\" \"potential,\" \"predict,\" \"seek,\" \"should,\"\n\"would,\" \"contemplate,\" \"project,\" \"target,\" \"objective,\" or the negative\nversion of these words and similar expressions. In this press release,\nforward-looking statements include, but are not limited to, statements\nrelating to timing, size, terms and completion of the offering.\nForward-looking statements involve known and unknown risks, uncertainties and\nother factors that may cause NeOnc’s actual results, performance or\nachievements to be materially different from future results, performance or\nachievements expressed or implied by the forward-looking statements in this\npress release, including, without limitation, risks and uncertainties related\nto the timing, size, terms and completion of the offerings. NeOnc’s\nforward-looking statements are based upon its current expectations and involve\nassumptions that may never materialize or may prove to be incorrect. All\nforward-looking statements are expressly qualified in their entirety by these\ncautionary statements. For a detailed description of NeOnc’s risks and\nuncertainties, you are encouraged to review its documents filed with the SEC\nincluding NeOnc’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You\nare cautioned not to place undue reliance on forward-looking statements, which\nspeak only as of the date on which they were made. NeOnc undertakes no\nobligation to update such statements to reflect events that occur or\ncircumstances that exist after the date on which they were made, except as\nrequired by law.\n\nContacts\n\nCompany Contact:\ninfo@neonc.com\n\nInvestor Contact:\nJon Nugent\nJon Nugent Communications\njon@jonnugent.com\n205-566-3026\n\nThis press release was published by a CLEAR® Verified individual.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/24b1bfd4-b28d-443d-9ec2-0a30c1b76cee)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX90RCBp-20260909","title":"NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors","author":"Globe Newswire","ticker":"NTHI","created":"2026-09-09T12:00:01.350Z","tickers":["NTHI"],"exchange":"NASDAQ","article_body":"CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies\nHoldings, Inc. (Nasdaq: NTHI) (\"NeOnc\" or the \"Company\"), a multi-Phase 2\nclinical-stage biopharmaceutical company developing novel therapies for\ncentral nervous system (CNS) cancers, today announced that it has entered into\ndefinitive securities purchase agreements with new and existing healthcare\nfocused institutional investors for the purchase and sale of 3,571,430 shares\nof the Company’s common stock (or pre-funded warrants to purchase shares of\ncommon stock in lieu thereof) and accompanying warrants to purchase up to\n3,571,430 shares of the Company’s common stock at a combined purchase price\nof $4.20 per share (or $4.1999 per pre-funded warrant) and accompanying\nwarrant in a registered direct offering priced at-the-market under Nasdaq\nrules. Each pre-funded warrant will be exercisable upon issuance at an\nexercise price of $0.0001 per share and will expire when exercised in full.\nEach warrant will be immediately exercisable at an exercise price of $4.20 per\nshare and will expire five years from the date of issuance.\n\nThe gross proceeds to the Company from the registered direct offering are\nestimated to be approximately $15 million before deducting the placement\nagent’s fees and other estimated offering expenses. The offering is expected\nto close on or about September 10, 2026, subject to the satisfaction of\ncustomary closing conditions.\n\nRoth Capital Partners and A.G.P./Alliance Global Partners are acting as\nco-placement agents.\n\nThe registered direct offering of the securities is being made pursuant to a\nshelf registration statement on Form S-3 (File No. 333-294845) previously\nfiled by the Company with the U.S. Securities and Exchange Commission (\"SEC\")\nand became effective on April 9, 2026. The offering is being made only by\nmeans of a prospectus forming part of the effective registration statement\nrelating to the offering. A final prospectus supplement and accompanying\nprospectus describing the terms of the offering will be filed with the SEC and\nwill be available on the SEC’s website located at https://www.sec.gov.\nElectronic copies of the final prospectus supplement and the accompanying\nprospectus may be obtained, when available, by contacting Roth Capital\nPartners, LLC at 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660,\nAttn: Prospectus Department, telephone: 800-678-9147 or by email at\nrothecm@roth.com, or A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th\nFloor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at\nprospectus@allianceg.com.\n\nThis press release does not constitute an offer to sell or the solicitation of\nan offer to buy, nor will there be any sales of such securities in any\njurisdiction in which such offer, solicitation or sale would be unlawful prior\nto registration or qualification under the securities laws of such\njurisdiction. Copies of the prospectus supplement relating to the registered\ndirect offering, together with the accompanying base prospectus will be filed\nby the Company and, upon filing, can be obtained at the SEC’s website at\nwww.sec.gov.\n\nAbout NeOnc Technologies Holdings, Inc.\n\nNeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company\nfocused on the development and commercialization of central nervous system\ntherapeutics that are designed to address the persistent challenges in\novercoming the blood-brain barrier. The company’s NEO™ drug development\nplatform has produced a portfolio of novel drug candidates and delivery\nmethods with patent protections extending to 2038. These proprietary\nchemotherapy agents have demonstrated positive effects in laboratory tests on\nvarious types of cancers and in clinical trials treating malignant gliomas.\nNeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical\ntrials and are advancing under FDA Fast-Track and Investigational New Drug\n(IND) status. The company has exclusively licensed an extensive worldwide\npatent portfolio from the University of Southern California consisting of\nissued patents and pending applications related to NEO100, NEO212, and other\nproducts from the NeOnc patent family for multiple uses, including oncological\nand neurological conditions.\n\nFor more about NeOnc and its pioneering technology, visit https://neonc.com.\n\nForward-Looking Statements\n\nNeOnc cautions you that all statements, other than statements of historical\nfacts, contained in this press release, are forward-looking statements.\nForward-looking statements, in some cases, can be identified by terms such as\n\"believe,\" \"may,\" \"will,\" \"estimate,\" \"continue,\" \"anticipate,\" \"design,\"\n\"intend,\" \"expect,\" \"could,\" \"plan,\" \"potential,\" \"predict,\" \"seek,\" \"should,\"\n\"would,\" \"contemplate,\" \"project,\" \"target,\" \"objective,\" or the negative\nversion of these words and similar expressions. In this press release,\nforward-looking statements include, but are not limited to, statements\nrelating to timing, size, terms and completion of the offering.\nForward-looking statements involve known and unknown risks, uncertainties and\nother factors that may cause NeOnc’s actual results, performance or\nachievements to be materially different from future results, performance or\nachievements expressed or implied by the forward-looking statements in this\npress release, including, without limitation, risks and uncertainties related\nto the timing, size, terms and completion of the offerings. NeOnc’s\nforward-looking statements are based upon its current expectations and involve\nassumptions that may never materialize or may prove to be incorrect. All\nforward-looking statements are expressly qualified in their entirety by these\ncautionary statements. For a detailed description of NeOnc’s risks and\nuncertainties, you are encouraged to review its documents filed with the SEC\nincluding NeOnc’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You\nare cautioned not to place undue reliance on forward-looking statements, which\nspeak only as of the date on which they were made. NeOnc undertakes no\nobligation to update such statements to reflect events that occur or\ncircumstances that exist after the date on which they were made, except as\nrequired by law.\n\nContacts\n\nCompany Contact:\ninfo@neonc.com\n\nInvestor Contact:\nJon Nugent\nJon Nugent Communications\njon@jonnugent.com\n205-566-3026\n\nThis press release was published by a CLEAR® Verified individual.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/24b1bfd4-b28d-443d-9ec2-0a30c1b76cee)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-09T12:00:01.399396159Z","server_sent_at_ms":1788955201399},"received_at":"2026-09-09T12:00:01.451Z","source_url":null},"analysis":{"id":"127889","press_release_id":"139044","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["use of proceeds not disclosed in the offering announcement","100% warrant coverage (3,571,430 five-year warrants) creates additional contingent dilution","combined share-plus-warrant pricing means effective per-share consideration is below the $4.20 headline price"],"eventType":"offering","narrative":"NeOnc Technologies priced a $15 million registered direct offering at a combined $4.20 per share with new and existing healthcare-focused institutional investors, priced at-the-market under Nasdaq rules.\n\nThe deal covers 3,571,430 shares (or pre-funded warrants in lieu) with accompanying five-year warrants to buy another 3,571,430 shares at $4.20; Roth Capital Partners and A.G.P./Alliance Global Partners are co-placement agents, with closing expected on or about September 10, 2026.\n\nGross proceeds are approximately $15 million before fees and expenses, and the release discloses no specific use of proceeds; the raise funds a Phase 2 CNS oncology pipeline led by NEO100 and NEO212, which are advancing under FDA Fast-Track and IND status with USC-licensed patents extending to 2038.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"At-the-market $15M raise with full warrant coverage -- small-cap biotech dilution to monitor into the September 10 close."},"keyFigures":{"dealValueUsd":15000000,"offeringPrice":4.2,"sharesOffered":3571430,"customDimensions":{"warrant_term":"five years from issuance","expected_close":"on or about September 10, 2026","gross_proceeds":"$15 million","warrant_shares":3571430,"warrant_exercise_price":4.2,"prefunded_warrant_combined_price":4.1999,"prefunded_warrant_exercise_price":0.0001}},"namedEntities":{"people":[],"products":["NEO100","NEO212","NEO platform"],"companies":[{"name":"NeOnc Technologies Holdings, Inc.","ticker":"NTHI","relationship":"issuer/filer"},{"name":"Roth Capital Partners","relationship":"co-placement agent"},{"name":"A.G.P./Alliance Global Partners","relationship":"co-placement agent"},{"name":"University of Southern California","relationship":"patent licensor"}],"dollarAmounts":[{"amount":"$15 million","context":"estimated gross proceeds before placement agent fees and offering expenses"},{"amount":"$4.20","context":"combined purchase price per share (or pre-funded warrant) plus accompanying warrant; also the warrant exercise price"},{"amount":"$4.1999","context":"combined purchase price per pre-funded warrant and accompanying warrant"},{"amount":"$0.0001","context":"pre-funded warrant exercise price"}]},"materialImpact":{"score":3,"reasoning":"A $15 million registered direct offering with 100% warrant coverage is meaningfully dilutive for a small-cap clinical-stage biotech. At-the-market pricing under Nasdaq rules and no stated discount keep it below a 4, but the attached five-year warrants lower effective consideration and create a dilution overhang."},"tickerRelevance":{"others":[],"primary":"NTHI"},"globalImportance":22,"audienceRelevance":18,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"registered direct offering with warrant coverage","issuerAuthored":true,"dilutionOverhang":"additional 3,571,430 warrant shares","pricingStructure":"at-the-market under Nasdaq rules","useOfProceedsDisclosed":false}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":3,"narrative":"NeOnc Technologies priced a $15 million registered direct offering at a combined $4.20 per share with new and existing healthcare-focused institutional investors, priced at-the-market under Nasdaq rules.\n\nThe deal covers 3,571,430 shares (or pre-funded warrants in lieu) with accompanying five-year warrants to buy another 3,571,430 shares at $4.20; Roth Capital Partners and A.G.P./Alliance Global Partners are co-placement agents, with closing expected on or about September 10, 2026.\n\nGross proceeds are approximately $15 million before fees and expenses, and the release discloses no specific use of proceeds; the raise funds a Phase 2 CNS oncology pipeline led by NEO100 and NEO212, which are advancing under FDA Fast-Track and IND status with USC-licensed patents extending to 2038.","key_figures":{"dealValueUsd":15000000,"offeringPrice":4.2,"sharesOffered":3571430,"customDimensions":{"warrant_term":"five years from issuance","expected_close":"on or about September 10, 2026","gross_proceeds":"$15 million","warrant_shares":3571430,"warrant_exercise_price":4.2,"prefunded_warrant_combined_price":4.1999,"prefunded_warrant_exercise_price":0.0001}},"named_entities":{"people":[],"products":["NEO100","NEO212","NEO platform"],"companies":[{"name":"NeOnc Technologies Holdings, Inc.","ticker":"NTHI","relationship":"issuer/filer"},{"name":"Roth Capital Partners","relationship":"co-placement agent"},{"name":"A.G.P./Alliance Global Partners","relationship":"co-placement agent"},{"name":"University of Southern California","relationship":"patent licensor"}],"dollarAmounts":[{"amount":"$15 million","context":"estimated gross proceeds before placement agent fees and offering expenses"},{"amount":"$4.20","context":"combined purchase price per share (or pre-funded warrant) plus accompanying warrant; also the warrant exercise price"},{"amount":"$4.1999","context":"combined purchase price per pre-funded warrant and accompanying warrant"},{"amount":"$0.0001","context":"pre-funded warrant exercise price"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-09T12:02:23.299Z","global_importance":22,"audience_relevance":18,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"registered direct offering with warrant coverage","issuerAuthored":true,"dilutionOverhang":"additional 3,571,430 warrant shares","pricingStructure":"at-the-market under Nasdaq rules","useOfProceedsDisclosed":false}},"durationMs":47752,"modelName":"glm-5.3-flash"}}